Michael Chen, MD
Interventional Cardiology · Rockville, MDNPI 1184650954
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $199,462 of the $241,415 with a category attached, or 82.6%. 40 manufacturers reported payments, led by Merck at 30.9% of the total. Reporting peaked in 2023 at $106,334 and has fallen 87.6% since, to $13,226 in 2025. Among interventional cardiology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 897 payments — averaging $269.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$75K
- Lilly USA, LLC$52K
- Boehringer Ingelheim$49K
- AstraZeneca$33K
- Lexicon Pharmaceuticals, Inc.$24K
- Novo Nordisk$1K
- plus $9K from 34 others
Across 27 payments — averaging $16,194 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$437K
What the payments were for
- Speaking & faculty fees$199,46283%
- Travel & lodging$24,64710%
- Food & beverage$17,1207%
- Education$1870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 120 | $74,598 |
| Lilly USA, LLC | 72 | $51,571 |
| Boehringer Ingelheim | 88 | $48,618 |
| AstraZeneca | 124 | $32,506 |
| Lexicon Pharmaceuticals, Inc. | 46 | $23,771 |
| Novo Nordisk | 59 | $1,472 |
| Abbott | 13 | $1,280 |
| Johnson & Johnson | 62 | $1,203 |
| Amgen | 52 | $1,109 |
| E.r. Squibb & Sons, L.L.C. | 54 | $912 |
| Novartis | 38 | $648 |
| Amarin Pharma, Inc. | 30 | $521 |
| Esperion Therapeutics, Inc. | 12 | $497 |
| Bayer | 19 | $373 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $371 |
| Pfizer | 18 | $341 |
| Boston Scientific | 3 | $174 |
| Medtronic(2 entities) | 2 | $161 |
| Kiniksa Pharmaceuticals, Ltd. | 7 | $136 |
| Scpharmaceuticals Inc. | 6 | $136 |
| Irhythm Technologies, Inc. | 1 | $103 |
| Kowa Pharmaceuticals America, Inc. | 8 | $102 |
| Philips North America LLC | 5 | $95 |
| Aerin Medical Inc. | 1 | $91 |
| Sanofi-aventis U.S. LLC | 6 | $86 |
| Atricure, Inc. | 3 | $67 |
| Edwards Lifesciences | 4 | $66 |
| Daiichi Sankyo Inc. | 3 | $65 |
| Regeneron Healthcare Solutions, Inc. | 5 | $65 |
| Baxter Healthcare | 2 | $58 |
| Cook Medical LLC | 2 | $46 |
| Gilead | 3 | $36 |
| GSK | 1 | $26 |
| Bridgebio Pharma, Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Abiomed | 1 | $19 |
| Inari Medical, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
| AbbVie | 1 | $11 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$146,178
- JARDIANCE$95,867
- FARXIGA$30,677
- Inpefa$22,982
- Xience V coronary stent system$729
- BRILINTA$579
- NEXLIZET$364
- NEXLETOL$364
- Repatha$244
- Ozempic$239
- MitraClip System$136
- WATCHMAN Access System$126
- VenaSeal$125
- ENTRESTO$112
- CAMZYOS$105
- Zio monitor$103
- ZIO XT Patch$103
How this compares
$241,415 in reported general payments places this provider in the 95th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 448 | $576,723 |
| EntrestoSacubitril/Valsartan | 276 | $391,980 |
| XareltoRivaroxaban | 146 | $186,295 |
| FarxigaDapagliflozin Propanediol | 150 | $181,449 |
| JardianceEmpagliflozin | 103 | $127,240 |
| Repatha SureclickEvolocumab | 99 | $101,781 |
| BrilintaTicagrelor | 73 | $77,344 |
| VerquvoVericiguat | 33 | $40,471 |
| VascepaIcosapent Ethyl | 28 | $27,083 |
| Praluent PenAlirocumab | 30 | $17,765 |
| Repatha SyringeEvolocumab | 22 | $16,164 |
| Ranolazine ErRanolazine | 97 | $14,854 |
| Metoprolol Succinate | 746 | $13,704 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $12,924 |
| MounjaroTirzepatide | 12 | $12,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $341 | $576,723448 claims |
| NovartisEntresto | $648 | $391,980276 claims |
| AstraZenecaFarxiga, Brilinta | $32,506 | $258,793223 claims |
| Johnson & JohnsonXarelto | $1,203 | $186,295146 claims |
| Boehringer IngelheimJardiance | $48,618 | $127,240103 claims |
| MerckVerquvo | $74,598 | $40,47133 claims |
| Esperion Therapeutics, Inc.Nexlizet | $497 | $12,92413 claims |
| Lilly USA, LLCMounjaro | $51,571 | $12,91112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 71 interventional cardiology providers in Maryland.
Other interventional cardiology in Rockville
- Vinay SatwahGreenbelt$679K
- Aloke FinnBaltimore$575K
- John WangBaltimore$138K
- Steven HearneSalisbury$100K
- Amir NajafiBel Air$82K
- Diljon ChahalBaltimore$78K
- Joseph CinderellaSalisbury$72K
- Ali TabrizchiBel Air$66K
- Homam IbrahimSilver Spring$49K
- Jon ResarBaltimore$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.